These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 1584187)

  • 1. Treatment strategies for extension of levodopa effect.
    LeWitt PA
    Neurol Clin; 1992 May; 10(2):511-26. PubMed ID: 1584187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mid-stage parkinsonism with mild motor fluctuations.
    Tolosa E; Valldeoriola F
    Clin Neuropharmacol; 1994; 17 Suppl 2():S19-31. PubMed ID: 9358192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa therapeutics: new treatment strategies.
    LeWitt PA
    Neurology; 1993 Dec; 43(12 Suppl 6):S31-7. PubMed ID: 8264909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New and emerging strategies for improving levodopa treatment.
    Tolosa ES; Valldeoriola F; Martí MJ
    Neurology; 1994 Jul; 44(7 Suppl 6):S35-44. PubMed ID: 8047259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.
    Rinne UK
    J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Initial treatment of Parkinson's disease].
    Kulisevsky J; López-Villegas D
    Rev Neurol; 1997 Aug; 25 Suppl 2():S163-9. PubMed ID: 9280684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the delivery of treatments for Parkinson's disease.
    Johnston TH; Fox SH; Brotchie JM
    Expert Opin Drug Deliv; 2005 Nov; 2(6):1059-73. PubMed ID: 16296809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of levodopa-induced motor complications.
    Stocchi F; Tagliati M; Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors.
    Olanow CW; Obeso JA
    Neurology; 2000; 55(11 Suppl 4):S72-7; discussion S78-81. PubMed ID: 11147513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson's disease therapy: treatment of early and late disease.
    Jankovic J
    Chin Med J (Engl); 2001 Mar; 114(3):227-34. PubMed ID: 11780303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
    Youdim MB
    J Neural Transm Suppl; 1986; 22():91-105. PubMed ID: 3097263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa: past, present, and future.
    Hauser RA
    Eur Neurol; 2009; 62(1):1-8. PubMed ID: 19407449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon.
    Tse W
    J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):12-7. PubMed ID: 17948614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
    Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of L-deprenyl in chronic levodopa treated parkinsonian patients.
    Streifler M; Rabey MJ
    J Neural Transm Suppl; 1983; 19():265-72. PubMed ID: 6421992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.